Brainsway Ltd.(BWAY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BWAY Brainsway Ltd.

Pre-Mkt 01-12 08:38:13 EST

23.11

+0.02

+0.09%

盘前24.83

+1.72+7.44%

08:33 EST

High23.41	Low22.22	Vol101.54K
Open23.41	D1 Closing23.09	Amplitude5.15%
Mkt Cap452.43M	Tradable Cap279.40M	Total Shares19.58M
T/O2.33M	T/O Rate0.84%	Tradable Shares12.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BWAY","market":"US","secType":"STK","nameCN":"Brainsway Ltd.","latestPrice":23.11,"timestamp":1767992400000,"preClose":23.09,"halted":0,"volume":101537,"hourTrading":{"tag":"盘前","latestPrice":24.83,"preClose":23.11,"latestTime":"08:33 EST","volume":13621,"amount":330333.7678,"timestamp":1768224827651},"delay":0,"floatShares":12089886,"shares":19577100,"eps":0.255754,"marketStatus":"Pre-Mkt","change":0.02,"latestTime":"01-12 08:38:13 EST","open":23.41,"high":23.41,"low":22.22,"amount":2334710.707678,"amplitude":0.051537,"askPrice":24.95,"askSize":388,"bidPrice":24.71,"bidSize":206,"shortable":3,"etf":0,"ttmEps":0.255754,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768228200000},"marketStatusCode":1,"adr":0,"adrRate":2,"listingDate":1555473600000,"exchange":"NASDAQ","adjPreClose":23.11,"preHourTrading":{"tag":"盘前","latestPrice":24.83,"preClose":23.11,"latestTime":"08:33 EST","volume":13621,"amount":330333.7678,"timestamp":1768224827651},"postHourTrading":{"tag":"盘后","latestPrice":22.7,"preClose":23.11,"latestTime":"19:35 EST","volume":183,"amount":4153.91,"timestamp":1768005319454},"volumeRatio":0.6080853665045636,"impliedVol":0.3809,"impliedVolPercentile":0.44},"requestUrl":"/m/hq/s/BWAY","defaultTab":"news","newsList":[{"id":"2602517210","title":"Brainsway announces U.S. FDA granted PMA for Neurolief’s ProlivRx system","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517210","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517210?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:47","pubTimestamp":1768222021,"startTime":"0","endTime":"0","summary":"BrainsWay (BWAY) announced that the U.S. Food and Drug Administration, FDA, has granted Premarket Approval, PMA, for Neurolief’s ProlivRx system, a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/brainsway-announces-u-s-fda-granted-pma-for-neuroliefs-prolivrx-system-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/brainsway-announces-u-s-fda-granted-pma-for-neuroliefs-prolivrx-system-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2601806052","title":"Brainsway Says Premera Blue Cross Blue Shield Expands Coverage to Include Depression Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806052","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806052?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:03","pubTimestamp":1767794588,"startTime":"0","endTime":"0","summary":"Brainsway Ltd  said Wednesday that Premera Blue Cross Blue Shield, a nonprofit health insurer, has adopted a new medical policy that expands coverage to include patients ages 15 and older with moderate to severe major depressive disorder treated with BrainsWay's accelerated SWIFT Deep TMS protocol.The protocol consists of five 10-minute treatment sessions per day for six days, followed by two sessions per day once a week for four weeks, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BWAY","BK4082"],"gpt_icon":0},{"id":"2589900358","title":"Brainsway Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2589900358","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589900358?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:47","pubTimestamp":1765198020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BWAY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 07:47 ET (12:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2589332490","title":"Brainsway Ltd : H.c. Wainwright Raises Target Price to $24 From $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2589332490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589332490?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:31","pubTimestamp":1765193477,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE0PO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2584627235","title":"BrainsWay Begins Clinical Trial of Deep TMS 360 System in Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2584627235","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584627235?lang=en_us&edition=fundamental","pubTime":"2025-11-17 23:59","pubTimestamp":1763395174,"startTime":"0","endTime":"0","summary":"BrainsWay  said Monday it has launched a multicenter clinical trial to assess its Deep TMS 360 system in people with alcohol use disorder.The randomized, double-blind trial will enroll over 200 adults with moderate to severe AUD for about six months of active or sham treatment, with the proportion of patients reporting no heavy drinking days during the first four months of treatment as primary endpoint, the company said.Participants will also receive behavioral and educational support during the study, BrainsWay said.The trial will take place at multiple sites in the US, Israel, and Sweden, it added.Shares of BrainsWay were down about 3% in recent trading Monday.Price: 15.29, Change: -0.47, Percent Change: -2.98","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BWAY","BK4082"],"gpt_icon":0},{"id":"2583594176","title":"Brainsway price target raised to $18 from $17 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2583594176","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583594176?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:35","pubTimestamp":1763048116,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Brainsway (BWAY) to $18 from $17 and keeps a Buy rating on the shares. The firm notes BrainsWay a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/brainsway-price-target-raised-to-18-from-17-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/brainsway-price-target-raised-to-18-from-17-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BWAY","BK4082"],"gpt_icon":0},{"id":"2583647495","title":"BrainsWay Receives FDA Clearance for Adolescent Depression Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2583647495","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583647495?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:01","pubTimestamp":1763035294,"startTime":"0","endTime":"0","summary":"BrainsWay  said Thursday it received US Food and Drug Administration clearance to offer its deep transcranial magnetic stimulation as an add-on treatment for major depressive disorder in patients aged 15 to 21.The therapy uses magnetic pulses to stimulate brain areas tied to mood and is intended to be used alongside existing care, the company said.The FDA decision was backed by real-world data from 1,120 adolescents that showed about two-thirds met response after 36 sessions and average symptoms fell by roughly 12 points on a standard depression scale, BrainsWay said.Safety outcomes were consistent with adult use, and clinicians can now use the same system for adults who failed antidepressants and for adolescents as an adjunct, the company added.Shares of the company were up over 2.2% in recent Thursday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2583569037","title":"Brainsway’s Deep TMS device granted FDA clearance in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569037","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583569037?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:11","pubTimestamp":1763032292,"startTime":"0","endTime":"0","summary":"BrainsWay (BWAY) announced that the FDA has granted a label expansion for the Deep Transcranial Magnetic Stimulation, or Deep TMS, system making th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/brainsways-deep-tms-device-granted-fda-clearance-in-major-depressive-disorder-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/brainsways-deep-tms-device-granted-fda-clearance-in-major-depressive-disorder-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2583304301","title":"Brainsway Is Maintained at Outperform by Northland Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2583304301","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583304301?lang=en_us&edition=fundamental","pubTime":"2025-11-13 02:18","pubTimestamp":1762971480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BWAY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 13:18 ET (18:18 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2582393648","title":"Brainsway Ltd : Northland Capital Raises Target Price to $23 From $19","url":"https://stock-news.laohu8.com/highlight/detail?id=2582393648","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582393648?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:15","pubTimestamp":1762877735,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nFWN3WN1D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2582366285","title":"BrainsWay Q3 EPS $0.04 Misses $0.07 Estimate, Sales $13.512M Beat $13.041M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366285","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366285?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:30","pubTimestamp":1762864247,"startTime":"0","endTime":"0","summary":"BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.07 by 42.86 percent. This is a 100 percent increase over earnings of $0.02 per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48776501/brainsway-q3-eps-0-04-misses-0-07-estimate-sales-13-512m-beat-13-041m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2582366277","title":"Press Release: BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366277","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366277?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:30","pubTimestamp":1762864200,"startTime":"0","endTime":"0","summary":"Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024. Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024. FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder . Raised midpoint of full-year 2025 Revenue and EBITDA guidance. BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025  -- BrainsWay Ltd.  , a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2025 financial results and provided an operational update.-- Revenue in the third quarter of 2025 increased 29% to $13.5 million,-- Currently have $65 million in remaining performance obligations from. of 2025, a 43% increase compared to the same period last year. Total. installed base now stands at more than 1,600 systems.-- Gross margin for the third quarter of 2025 was 75%, compared to 74% in. -- Net profit for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4082","TM","BK4604","BWAY","03160","BK4099","BK4585","BK4588"],"gpt_icon":0},{"id":"2581881649","title":"Brainsway Ltd  expected to post earnings of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881649","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881649?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:45","pubTimestamp":1762526708,"startTime":"0","endTime":"0","summary":"Brainsway Ltd  expected to post earnings of6cents a share - Earnings Preview Brainsway Ltd BWAY.OQ, BWAY.O is expected to  show a rise in quarterly revenue when it reports  results on November 11 for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1ZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2568490262","title":"Northland Securities Sticks to Their Buy Rating for Brainsway (BWAY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568490262","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568490262?lang=en_us&edition=fundamental","pubTime":"2025-09-17 23:15","pubTimestamp":1758122157,"startTime":"0","endTime":"0","summary":"Northland Securities analyst Carl Byrnes maintained a Buy rating on Brainsway today and set a price target of $19.00. The company’s shares opened t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/northland-securities-sticks-to-their-buy-rating-for-brainsway-bway-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/northland-securities-sticks-to-their-buy-rating-for-brainsway-bway-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BWAY"],"gpt_icon":0},{"id":"2567488831","title":"Brainsway Says US FDA Approves Accelerated Protocol for Major Depression Treatment System","url":"https://stock-news.laohu8.com/highlight/detail?id=2567488831","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567488831?lang=en_us&edition=fundamental","pubTime":"2025-09-16 21:04","pubTimestamp":1758027856,"startTime":"0","endTime":"0","summary":"BrainsWay  said Tuesday that the US Food and Drug Administration cleared an accelerated protocol for the company's deep transcranial magnetic stimulation system for the treatment of patients with major depressive disorder, including individuals with comorbid anxiety symptoms.The expanded clearance was based on data from a study that showed using the accelerated protocol to treat patients with the disorder resulted in outcomes comparable to the standard protocol but with fewer visits to the clinic, with no severe adverse events, the company said.The company said it will be training healthcare providers to use the accelerated protocol and to update reimbursement models to help with patient adoption.Shares of the company were up 4.7% in recent premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BWAY","BK4082"],"gpt_icon":0},{"id":"2567107737","title":"Brainsway receives FDA clearance for accelerated Deep TMS for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2567107737","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567107737?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:35","pubTimestamp":1758026138,"startTime":"0","endTime":"0","summary":"BrainsWay (BWAY) announced that the U.S. Food and Drug Administration, FDA, has granted an expansion of the cleared treatment protocols for the Com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/brainsway-receives-fda-clearance-for-accelerated-deep-tms-for-mdd-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/brainsway-receives-fda-clearance-for-accelerated-deep-tms-for-mdd-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BWAY","ABVC","BK4139"],"gpt_icon":0},{"id":"2562245049","title":"Brainsway Price Target Maintained With a $17.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2562245049","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562245049?lang=en_us&edition=fundamental","pubTime":"2025-08-25 19:13","pubTimestamp":1756120380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BWAY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 25, 2025 07:13 ET (11:13 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BWAY"],"gpt_icon":0},{"id":"2561076493","title":"Press Release: Neurolief Prepares for Launch of its Proliv(TM)Rx System for Major Depressive Disorder with Strategic Investment from BrainsWay","url":"https://stock-news.laohu8.com/highlight/detail?id=2561076493","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561076493?lang=en_us&edition=fundamental","pubTime":"2025-08-21 21:32","pubTimestamp":1755783120,"startTime":"0","endTime":"0","summary":"CORAL SPRINGS, Fla. and NETANYA, Israel, Aug. 21, 2025 /PRNewswire/ -- Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, today announced a strategic investment from BrainsWay Ltd. , a publicly-traded global leader in non-invasive neurostimulation treatments for mental health disorders. This investment marks a significant milestone as Neurolief awaits FDA approval and prepares for commercial launch of its ProlivRx, designed for the treatment of Major Depressive Disorder . The partnership reflects an exciting strategic alignment between the two companies, both of which are dedicated to expanding access to innovative, clinically validated and non-invasive mental health treatments.\"The ProlivRx therapy represents an ideal solution for patients who have","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4604","BWAY","BK4585","BK4588","BK4099","03160","BK4555","BK4082"],"gpt_icon":0},{"id":"2561467442","title":"BrainsWay Closes $5 Million Convertible Loan to Neurolief","url":"https://stock-news.laohu8.com/highlight/detail?id=2561467442","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561467442?lang=en_us&edition=fundamental","pubTime":"2025-08-21 20:10","pubTimestamp":1755778230,"startTime":"0","endTime":"0","summary":"BrainsWay  said Thursday it has closed a $5 million convertible loan to Neurolief, developer of a wearable brain neuromodulation platform for at-home use.The agreement includes milestone-based funding of an additional up to $6 million convertible loan upon US Food and Drug Administration approval of Proliv Rx device for major depressive disorder, and up to $5 million equity investment linked to revenue milestones, BrainsWay said.BrainsWay said it also received a call option to acquire all of Neurolief's equity at a price linked to enterprise value or a revenue multiple.Shares of BrainsWay were up more than 4% in recent premarket activity Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BWAY"],"gpt_icon":0},{"id":"2560810563","title":"BrainsWay to Acquire Minority Stake in Colorado Mental Health Clinics Operator","url":"https://stock-news.laohu8.com/highlight/detail?id=2560810563","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560810563?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:27","pubTimestamp":1755692834,"startTime":"0","endTime":"0","summary":"BrainsWay  said Wednesday it will invest an initial $2.3 million to acquire a minority stake in Axis Integrated Mental Health, a management services organization with several mental health clinics in Colorado.A potential $1 million in additional investment will be dependent on the achievement of milestones, the company said.The move follows a deal in June to invest $5 million for a minority stake in Stella MSO, a management services organization servicing over 20 mental health clinics in the US and Israel.The investments are part of a broader initiative \"to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy,\" BrainsWay said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NPL.SI","BK4082","BWAY","BK6100"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.brainsway.com","stockEarnings":[{"period":"1week","weight":0.198},{"period":"1month","weight":0.2911},{"period":"3month","weight":0.5325},{"period":"6month","weight":0.8773},{"period":"1year","weight":1.4023},{"period":"ytd","weight":0.215}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, the Asia Pacific, Europe, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.046299},{"month":2,"riseRate":0.5,"avgChangeRate":-0.011832},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.059774},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.049808},{"month":5,"riseRate":0.571429,"avgChangeRate":0.084065},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.010757},{"month":7,"riseRate":0.571429,"avgChangeRate":0.035205},{"month":8,"riseRate":0.714286,"avgChangeRate":0.108353},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.025595},{"month":10,"riseRate":0.428571,"avgChangeRate":0.000921},{"month":11,"riseRate":0.571429,"avgChangeRate":0.066538},{"month":12,"riseRate":0.714286,"avgChangeRate":0.084647}],"exchange":"NASDAQ","name":"Brainsway Ltd.","nameEN":"Brainsway Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Brainsway Ltd.(BWAY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Brainsway Ltd.(BWAY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Brainsway Ltd.,BWAY,Brainsway Ltd.股票,Brainsway Ltd.股票老虎,Brainsway Ltd.股票老虎国际,Brainsway Ltd.行情,Brainsway Ltd.股票行情,Brainsway Ltd.股价,Brainsway Ltd.股市,Brainsway Ltd.股票价格,Brainsway Ltd.股票交易,Brainsway Ltd.股票购买,Brainsway Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Brainsway Ltd.(BWAY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Brainsway Ltd.(BWAY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}